Our approach uses DenovAI’s proprietary end-to-end platform for de novo protein design. We took in as input the 2VSM target structure and elected nanobodies as the binder design modality. In order to maximize for binder designs that would be functional, we included residues 304,458,504 and 581 within the chosen design epitope. Following filtration, the best candidate was selected.